Brief: DBP And Vivo Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
17/09/2023 10:02
Sept 17 (Reuters) - Double Bond Pharmaceutical
International Ab (Publ) DBPHAb.TE :
* DBP INTERNATIONAL AB AND VIVO BIOPHARMA LLC ENTER INTO
ASSET
PURCHASE AND COLLABORATION AGREEMENTS TO DEVELOP AND
COMMERCIALIZE A NOVEL GLIOBLASTOMA TREATMENT
* DOUBLE BOND PHARMACEUTICAL- VIVO WILL ACQUIRE SI-053,
RELATED
ASSETS TO ADVANCE CLINICAL PROGRAM WITH DBP'S COLLABORATION TO
SUPPORT VIVO'S EFFORTS
* CLOSING IS CONDITIONED BY VIVO COMPLETING FINANCING
* DOUBLE BOND PHARMACEUTICAL - DBP IS ENTITLED TO RECEIVE
MORE
THAN $150 MILLION OF MILESTONE AND ROYALTY PAYMENTS FROM VIVO
Source text for Eikon: ID:nWkr5F9mZy
Further company coverage: DBPHAb.TE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Double Bond Pharmaceutical International AB (publ)
See all newsBrief: DBP International AB And Vivo Biopharma LLC Revised Asset Purchase And Collaboration Agreements
Brief: DBP International AB And Vivo Biopharma LLC Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: DBP And Vivo Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: Double Bond Pharmaceutical Says Positive Response For SI-053 From Ethical Committee In Netherlands Has Been Received
Brief: Double Bond To Cooperate With Belarus State Medical University